Biodel Inc., of Danbury, Conn., appointed Alan Krasner chief medical officer.

Biogen Idec Inc., of Cambridge, Mass., named Hans Peter Hasler chief operating officer.

BioReliance Corp., of Rockville, Md., named Tomoko Kotani representative director of the BioReliance KK office in Tokyo.

Cambrex, of East Rutherford, N.J., appointed Steven M. Klosk president, CEO, and board member. John R. Miller will serve as nonexecutive chairman.

CellCyte Genetics Corp., of Bothell, Wash., appointed Jay H. Traverse to its scientific advisory board.

Cellerix, of Madrid, Spain, appointed Guillermo Sellers vice president of medical and regulatory affairs.

Cytokinetics Inc., of South San Francisco, appointed Denise M. Gilbert to its board and to its nominating and governance committee.

DermTech, of La Jolla, Calif., named Herbert A. Fritsche to its scientific advisory board.

Diffusion Pharmaceuticals LLC, of Charlottesville, Va., appointed Mark T. Giles to its board.

EyeGate Pharma, of Waltham, Mass., appointed Praveen Tyle to its board.

Genmab A/S, of Copenhagen, Denmark, appointed David A. Eatwell chief financial officer.

Gen-Probe Inc., of San Diego, named Lucy Shapiro to its board.

Haemacure Corp., of Montreal, appointed Reinaldo M. Diaz to its board.

HTG Inc., of Tucson, Ariz., appointed Billie-Jo Kerns vice president of strategic marketing and business development.

Human Genome Sciences Inc., of Rockville, Md., named Kevin P. McRaith vice president of its hepatology franchise.

Inion Oy, of Tampere, Finland, promoted David Follows to chief operating officer.

Ipsen SA, of Paris, appointed Gerard Picot vice president of global regulatory affairs.

Javelin Pharmaceuticals Inc., of Cambridge, Mass., named Daniel Carr president and said Fred Mermelstein assumed the role of executive director.

Kosan Biosciences Inc., of Hayward, Calif., appointed Pamela S. Cohen senior vice president and chief medical officer.

Medicure Inc., of Winnipeg, Manitoba, appointed Dwayne Henley chief financial officer.

MediGene AG, of Martinsried, Germany, appointed Axel Mescheder executive board member for research and development.

Momenta Pharmaceuticals Inc., of Cambridge, Mass., appointed James R. Sulat to its board.

MonoSolRx, of Warren, N.J., appointed Vincent Viviani senior vice president of manufacturing and operations.

National Stem Cell Holding Inc., of Mountainside, N.J., appointed Kenneth D. Steiner chief operating officer.

Nektar Therapeutics Inc., of San Carlos, Calif., named Bharatt Chowrira chief operating officer and head of the PEGylation business unit.

Noven Pharmaceuticals Inc., of Miami, appointed Steven M. Dinh vice president and chief scientific officer.

Oncothyreon Inc., of Bellevue, Wash., named Daniel K. Spiegelman and Stephen K. Burley to its board.

Pantec Biosolutions AG, of Ruggell, Leichtenstein, appointed Burkhard Feurstein and Michael Armbruester to its board.

ProtAffin AG, of Graz, Austria, appointed Antal Rot to its scientific advisory board.

Proteolix Inc., of South San Francisco, appointed Thomas Kassberg executive vice president of corporate development.

Quintiles Transnational Corp., of Research Triangle Park, N.C., appointed Christopher H. Cabell chief medical and scientific officer.

Response Genetics Inc., of Los Angeles, named David M. Jackson executive vice president.

Senetek plc, of Napa, Calif., appointed Phillip Rose chief operating officer and retained J. David Bruner as a full-time marketing consultant.